Jasper Therapeutics Posts Q2 Loss, Guides Cash Runway to 2028 After Kira Merger
JSPR has more than doubled off its 52-week low of $0.315 on light trading volume (0.1× avg).
Summary
Jasper Therapeutics reported Q2 2026 results with a net loss of $2.8 million ($0.10 per share), beating estimates, and cash of $7.3 million as of June 30. The company completed its all-stock acquisition of Kira Pharmaceuticals in July and raised $132 million in a concurrent PIPE, extending its cash runway through the second half of 2028. Management highlighted pipeline milestones: interim data from the KP-104 Phase 2 basket trial in rare renal indications is expected in Q4 2026, a pre-BLA meeting for briquilimab is planned for Q1 2027, and a CTA/IND filing for KP-701 is targeted for Q1 2027. The company also faces a Nasdaq delisting risk with a November 30 deadline, as disclosed in its 10-Q filed today. The combined entity now has a broader clinical portfolio and sufficient capital to advance multiple programs, but the stock remains under $1 and going concern doubts persist.
At the time of this announcement, JSPR was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.3M. The 52-week trading range was $0.32 to $3.14. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.